However, the overactivation of NRF2 upregulates these drug-metabolizing enzymes, leading to enhanced drug metabolism and clearance in cancers like lung, colorectal, breast, and prostate cancer. The gene discussed is NFE2L2; the disease is prostate carcinoma.